India's pharmaceutical market recorded its fourth consecutive quarter of double-digit growth, with September 2026 sales reaching ₹70,180 crore. The expansion is fueled by rising demand for chronic therapies and a shift in market share toward larger, compliant manufacturers following tighter regulatory oversight.
The domestic pharmaceutical industry has maintained a steady growth trajectory, recording a 12% year-on-year increase in the September 2026 quarter with total sales reaching ₹70,180 crore. This marks the fourth consecutive quarter of double-digit expansion, a significant shift from the 6%-8% growth trends seen throughout 2025. Data indicates that the primary drivers of this performance are chronic therapy segments, such as cardiac, diabetes, and oncology treatments, which are seeing sustained demand as health awareness grows.
A major factor behind this shift is the consolidation of the market. The Central Drug Standard Control Organization (CDSCO) has enforced stricter quality control measures, specifically the revised Schedule M requirements for Good Manufacturing Practices (GMP). This has forced many small and medium-sized manufacturing units that could not meet these updated standards to stop operations. Consequently, market share has moved away from unorganized, smaller players toward larger, organized companies capable of investing in compliance and high-quality production.
Large pharmaceutical companies are reflecting these trends in their quarterly performance. Sun Pharma reported a 17.3% increase in its India formulation sales, reaching ₹5,552 crore, as its market reach expanded. Similarly, Mankind Pharma posted a 17.33% year-on-year rise in net sales, totaling ₹4,337.86 crore for the quarter. These figures highlight how established firms are absorbing the demand once served by smaller competitors, effectively turning regulatory compliance into a competitive advantage.
However, this growth is not uniform across all categories. While chronic care segments like anti-diabetic and cardiac therapies have recorded growth exceeding 20%, other areas such as anti-infectives remain stagnant. This disparity suggests that investors should look beyond aggregate industry figures to understand which specific segments are genuinely performing.
Furthermore, the sector faces certain risks that could affect profitability. Companies pursuing aggressive growth through acquisitions, such as recent deals involving Mankind Pharma and Sun Pharma, face the challenge of successfully integrating new businesses without putting too much pressure on their balance sheets. While the current regulatory environment favors large players, these companies must also manage the costs associated with continuous quality upgrades and potential supply chain fluctuations. The next key monitorable for the industry will be whether this double-digit growth trend can sustain itself amid evolving pricing pressures and whether these companies can successfully integrate their recent acquisitions to boost long-term earnings.